Trial · NCT00333840
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First-line Treatment Period | STARTED | Imatinib (STI571) | 553 | |
| First-line Treatment Period | STARTED | IFN-a + Ara-C | 553 | |
| First-line Treatment Period | STARTED | Imatinib to IFN-a + Ara-C | 0 | |
| First-line Treatment Period | STARTED | IFN-a + Ara-C to Imatinib | 0 | |
| First-line Treatment Period | Safety Population; Received Study Drug | Imatinib (STI571) | 551 | |
| First-line Treatment Period | Safety Population; Received Study Drug | IFN-a + Ara-C | 533 | |
| First-line Treatment Period | Safety Population; Received Study Drug | Imatinib to IFN-a + Ara-C | 0 | |
| First-line Treatment Period | Safety Population; Received Study Drug | IFN-a + Ara-C to Imatinib | 0 | |
| First-line Treatment Period | COMPLETED | Imatinib (STI571) | 267 | |
| First-line Treatment Period | COMPLETED | IFN-a + Ara-C | 7 | |
| First-line Treatment Period | COMPLETED | Imatinib to IFN-a + Ara-C | 0 | |
| First-line Treatment Period | COMPLETED | IFN-a + Ara-C to Imatinib | 0 | |
| First-line Treatment Period | NOT COMPLETED | Imatinib (STI571) | 286 | |
| First-line Treatment Period | NOT COMPLETED | IFN-a + Ara-C | 546 | |
| First-line Treatment Period | NOT COMPLETED | Imatinib to IFN-a + Ara-C | 0 | |
| First-line Treatment Period | NOT COMPLETED | IFN-a + Ara-C to Imatinib | 0 | |
| Second-line Treatment Period | STARTED | Imatinib (STI571) | 0 | |
| Second-line Treatment Period | STARTED | IFN-a + Ara-C | 0 | |
| Second-line Treatment Period | STARTED | Imatinib to IFN-a + Ara-C | 14 | |
| Second-line Treatment Period | STARTED | IFN-a + Ara-C to Imatinib | 363 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00333840/flow